-
If you purchased shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) and currently hold any of those NASDAQ:CPXX shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
June 3, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX), was announced concerning whether the takeover of Celator Pharmaceuticals. by Jazz Pharmaceuticals plc for $30.25 per share is unfair to NASDAQ:CPXX stockholders.
The investigation by a law firm concerns whether certain officers and directors of Celator Pharmaceuticals Inc breached their fiduciary duties owed to NASDAQ:CPXX investors in connection with the proposed acquisition.
On May 31, 2016, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that they have entered into an agreement for Jazz Pharmaceuticals to acquire Celator Pharmaceuticals Inc (NASDAQ:CPXX) for $30.25 per share in cash, or approximately $1.5 billion.
However, the investigation concerns whether the offer is unfair to NASDAQ:CPXX stockholders. More specifically, the investigation concerns whether the Celator Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) closed on June 1, 2016, at $30.20 per share.
